

Q4 18-19 Performance in Delivery 29.04.2019

Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
16/NW/0305	201856	A Phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of DYSPORT® for the treatment of urinary incontinence in subjec	Number Agreed	4	4	Date Agreed	30/09/2019	3	01/10/2018	3	Recruitment Finished	
17/NW/0698	233163	An International, Multi-Center, Open-Label, Randomized, Phase III Trial of Sacituzumab Govitecan versus Treatment of Physician Choice in Patients with Metastatic Triple-Negative Breast Cancer Who Received at Least Two Prior Treatments	Number Agreed	1	1	Date Agreed	31/12/2019	0	31/12/2018	0	Recruitment Finished	Study unexpectedly closed by Sponsor before recruitment began.